2 21 22 ABBREVIATED TITLE: Corticosterone, CYP17A1 and metabolic syndrome 23 ABSTRACT 46 Context and objective. Common genetic variants in CYP17A1 associate with higher blood pressure, 47 putatively from impaired 17-hydroxylase activity and mineralocorticoid excess. However, the same 48 variants protect against obesity and insulin resistance. We tested whether CYP17A1 variants that 49 enhance 17-hydroxylase activity cause 'relative corticosterone deficiency'. Since corticosterone is 50 thought to contribute disproportionately to negative feedback in the hypothalamic-pituitary-adrenal 51 axis, we also tested whether lower corticosterone associates with higher cortisol and hence with 52 metabolic syndrome. 53 54 Design: Cross-sectional studies within the population-based Orkney Complex Disease Study 55 (ORCADES; n=2018), VIKING Health Study Shetland (VIKING; n=2098), East Hertfordshire study 56 (EHERTS; n=279), Edinburgh Type 2 Diabetes Study (ET2DS; n=903), and the Swiss Kidney Project 57 on Genes in Hypertension (SKIPOGH; n=888). 58 59 Outcome measures. Cortisol and corticosterone in morning plasma samples in ORCADES, VIKING 60 and ET2DS, and in EHERTS in plasma following overnight dexamethasone suppression (0.25mg) 61 and 30 mins after ACTH 1-24 (1µg); cortisol and corticosterone metabolites in day and night urine 62 samples in SKIPOGH. Features of the metabolic syndrome including body mass index, systolic blood 63 pressure, lipid profile, fasting glucose, fasting insulin and HOMA-IR. 64 65 Results. In ORCADES, ET2DS and SKIPOGH, CYP17A1 variants were associated with 66 corticosterone:cortisol ratio. In ORCADES, VIKING and ET2DS there were consistent associations 67 of morning plasma cortisol and corticosterone with BMI, blood pressure, lipid profile, fasting glucose 68 and HOMA-IR. In EHERTS, however, after dexamethasone suppression and ACTH 1-24 stimulation, 69 impaired glucose tolerance and insulin sensitivity were associated with higher cortisol but lower 70 corticosterone. Similarly, in SKIPOGH, low corticosterone:cortisol metabolite ratios were associated 71 with high BMI and dyslipidemia. 98 Widely neglected in humans, corticosterone circulates at concentrations of 5-10 % those of cortisol. 99 However, concentrations of corticosterone in human cerebrospinal fluid and brain are relatively high, 100
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Conclusions. 'Relative corticosterone deficiency', due to a primary alteration in adrenal 74 steroidogenesis favouring cortisol over corticosterone, may mediate the associations of genetic 75 variation in CYP17A1 with metabolic syndrome. However, additional determinants of variation in 76 plasma corticosterone are likely to explain its generally positive associations with features of 77 metabolic syndrome. INTRODUCTION
79
In genome-wide association studies (GWAS) common variants in the CYP17A1 locus are consistently 80 associated with hypertension (1-4) and cardiovascular disease (5, 6) . CYP17A1 encodes the 81 steroidogenic enzyme CYP17A1, which is expressed in human but not rat or mouse adrenal cortex and 82 catalyses 17-hydroxylase activity, converting precursors for synthesis of 11-deoxycorticosterone and 83 corticosterone into 17-hydroxylated precursors for synthesis of 11-deoxycortisol and cortisol. Rare 84 mutations causing near-absent CYP17A1 activity result in low-renin hypertension (7), attributed to 85 accumulation of the mineralocorticoid 11-deoxycorticosterone. Ratios of steroid metabolites reflecting 86 CYP17A1 activity are highly heritable (8). Associations of more common variation in CYP17A1 with 87 hypertension might therefore be explained by reduced 17α-hydroxylase activity.
88
Intriguingly, CYP17A1 risk alleles for hypertension are also associated with lower body mass index 89 (BMI) (9-11) and enhanced insulin sensitivity (12). Conversely, alleles which are protective for 90 hypertension, and therefore predicted to increase 17-hydroxylase activity, confer increased risk of 91 obesity and insulin resistance. This paradox is unexplained, but may relate to variations in production 92 of the major glucocorticoid, cortisol. Elevated cortisol in Cushing's syndrome causes obesity and 93 insulin resistance, while plasma cortisol is more subtly increased in metabolic syndrome (13). However, 94 if elevated 17-hydroxylase activity contributes to obesity and insulin resistance by increasing cortisol 95 production, why would plasma cortisol concentration not be 'corrected' by enhanced negative feedback 96 suppression of ACTH secretion and a compensatory fall in cortisol production? An explanation may be 97 found by considering the role of the second glucocorticoid in humans, corticosterone. Figure 1A ), in VIKING (Coefficient 220 correlation = 0.08, p<0.001) and in both dexamethasone-suppressed and ACTH-stimulated samples in 221 EHERTS ( Figure 1B ), while urinary cortisol and corticosterone metabolites were positively correlated 222 in SKIPOGH ( Figure 1C and 1D). After ACTH stimulation in EHERTS, the increase from baseline was 223 greater for corticosterone than cortisol (6.2±0.3 vs 3.9±0.4 fold, respectively; p<0.001).
224
Associations of plasma corticosterone and cortisol with CYP17A1 genotype
225
In ORCADES, associations of functional SNPs in CYP17A1 with morning plasma cortisol and 226 corticosterone are shown in 
237
Associations of morning plasma cortisol and corticosterone with features of metabolic syndrome were associated with lower BMI. After adjustment for BMI, age and sex, both higher plasma cortisol 240 and corticosterone were associated with higher fasting plasma glucose and higher triglycerides, 241 although the magnitude of this association was greater for cortisol than corticosterone. Moreover, higher 244 these predominant associations with cortisol, lower corticosterone but not cortisol was associated with 245 lower HDL-cholesterol, while higher corticosterone but not cortisol was associated with higher fasting 246 insulin and HOMA-IR. The corticosterone:cortisol ratio was positively associated with fasting glucose, 247 insulin and HOMA-IR but not with BMI, blood pressure or lipid profile.
248
In VIKING (Table 3 and Figure 2B) , similar associations were observed as in ORCADES. Both cortisol 249 and corticosterone were negatively associated with BMI. Cortisol was more strongly positively 250 associated with systolic blood pressure and triglycerides than corticosterone. The corticosterone:cortisol 251 ratio was negatively associated with BMI and positively associated with fasting glucose.
252
In ET2DS (Table 3 and Figure 2C ), fewer biochemical phenotypes were available, but both higher 253 plasma cortisol and plasma corticosterone were associated with lower BMI and higher fasting plasma 254 glucose, as in ORCADES. However, cortisol and corticosterone were unrelated to systolic blood 255 pressure in ET2DS, and the corticosterone:cortisol ratio was not significantly associated with BMI, 256 blood pressure or glucose.
257 CYP17A1 with hypertension versus other features of metabolic syndrome. We therefore anticipated that 314 deficiency' is associated with cortisol-mediated insulin resistance and obesity. However, despite 315 elevated corticosterone excretion rate being reported previously in hypertension (36), we did not find 316 an association between morning plasma corticosterone and blood pressure. Moreover, our data show 317 that morning plasma cortisol and corticosterone were positively correlated. Further, plasma cortisol and 318 corticosterone showed similar associations with BMI; it is likely that reduced plasma corticosterone in 319 obesity is explained by increased activity of A-ring reductases which also underlie increased clearance 320 of cortisol in obesity (37). When we did find discrepancies in associations with plasma cortisol or 321 corticosterone, it was generally higher, rather than lower, morning plasma corticosterone that was the 322 stronger predictor than morning plasma cortisol, e.g. of fasting plasma glucose, plasma insulin and and previous studies investigating associations of glucocorticoid excess with dyslipidaemia have been 335 inconsistent (13). subjects who had received dexamethasone to suppress any compensatory increase or primary drive to 338 the HPA axis, and a fixed dose of ACTH 1-24 to stimulate cortisol and corticosterone. The results are 339 striking, with opposite associations of cortisol and corticosterone with metabolic syndrome features, consistent with a primary shift in adrenocortical production in favour of cortisol rather than 342 from the brain (15), corticosterone is thought to make a disproportionate contribution to negative 343 feedback suppression of the HPA axis in humans, these observations could provide a key insight into 344 the activation of the HPA axis and elevated plasma cortisol in metabolic syndrome. This insight is 345 obscured by measurement of morning plasma corticosterone and cortisol alone, perhaps because of 346 greater variability as a result of unmeasured confounding.
Associations of ACTH-stimulated cortisol and corticosterone with features of metabolic

347
Fasting plasma corticosterone was low in the ET2DS cohort, whereas cortisol was similar to the values 348 in the ORCADES cohort (mean corticosterone:cortisol was 3.0% in ET2DS vs. 7.5% in ORCADES, 349 p<0.0001). This is unlikely to be due to older age of the ET2DS cohort, since corticosterone:cortisol 350 ratio was not associated with age (r 2 = 0.01, p=0.27). Again, insulin deficiency might favour cortisol 351 rather than corticosterone secretion, consistent with loss of up-regulation of CYP17A1 by insulin (38).
352
If confirmed, this mechanism may exacerbate the 'relative corticosterone deficiency' apparent with 353 metabolic syndrome in EHERTS, and thereby exacerbate HPA axis activation in type 2 diabetes.
354
Given the limitations of morning plasma cortisol and corticosterone, we investigated the hypothesis of 355 relative corticosterone deficiency in another cohort, the SKIPOGH study, in which integrated 356 measurements of cortisol and corticosterone metabolite excretion in urine were available in a large 357 number of participants. These results confirmed that the pattern observed for plasma glucocorticoids 358 after ACTH 1-24 stimulation in EHERTS, with relatively low corticosterone and high cortisol, is similarly 359 associated in urine with glucose and lipid metabolism and, strikingly, with obesity. Surprisingly,
360
'relative corticosterone deficiency' was also associated with higher systolic clinic blood pressure, 361 although previous studies in this cohort have suggested that ambulatory blood pressure is inversely 362 associated with CYP17A1 activity only in the presence of high sodium intake (8). n/a 9.38 ± 0.14 n/a n/a n/a Plasma glucose 120 min after oral glucose (mM) n/a 7.13 ± 0.18 n/a n/a n/a Fasting plasma insulin mU/L 6.44 ± 0.10 7.18 ± 0.35 n/a 6.19 ± 0.21 8.31 ± 0.80 HOMA-IR 1.59 ± 0.34 1.96 ± 0.11 n/a 1.48 ± 0.06 1.86 ± 0.17 Daytime urinary steroids Tetrahydrodehydrocorticosterone (µg/day) n/a n/a n/a 67.3 ± 1.3 n/a Tetrahydrocorticosterone (µg/day) n/a n/a n/a 91.7 ± 1.7 n/a 5α-Tetrahydrocorticosterone (µg/day) n/a n/a n/a 188.5 ± 4.2 n/a Tetrahydrocortisol (µg/day) n/a n/a n/a 1080.5 ± 18.2 n/a 5α-Tetrahydrocortisol (µg/day) n/a n/a n/a 779.9 ± 20.8 n/a Tetrahydrocortisone (µg/day) n/a n/a n/a 1861.2 ± 33.8 n/a Nighttime urinary steroids Tetrahydrodehydrocorticosterone (µg/night) n/a n/a n/a 27.3 ± 0.7 n/a Tetrahydrocorticosterone (µg/night) n/a n/a n/a 41.8 ± 1 n/a 5α-Tetrahydrocorticosterone (µg/night) n/a n/a n/a 60.7 ± 1.7 n/a Tetrahydrocortisol (µg/night) n/a n/a n/a 362.9 ± 8.2 n/a 5α-Tetrahydrocortisol (µg/night) n/a n/a n/a 247.1 ± 6.8 n/a Tetrahydrocortisone (µg/night) n/a n/a n/a 642.6 ± 14.2 n/a Data presented as mean ± SEM. n/a = not available. * Dexamethasone suppressed in EHERTS cohort 
